Deficiency of the proapoptotic SAP function in X-linked lymphoproliferative disease aggravates Epstein-Barr virus (EBV) induced mononucleosis and promotes lymphoma development

Immunology Letters

Volumn 130, Issue 1-2, 2010, Pages 13-18

  Nagy, Noemi ^a   Klein, Eva ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Burkitt lymphoma; Epstein Barr virus; XLP

Indexed keywords

IMMUNOGLOBULIN; MYC PROTEIN; SERUM AMYLOID P; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN;

APOPTOSIS; B LYMPHOCYTE DIFFERENTIATION; BURKITT LYMPHOMA; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; DISEASE EXACERBATION; EPSTEIN BARR VIRUS; GENE MUTATION; GENETIC CODE; HUMAN; INFECTIOUS MONONUCLEOSIS; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS ACTIVATION; X CHROMOSOME LINKED DISORDER;

ANIMALS; APOPTOSIS; BURKITT LYMPHOMA; GENE DELETION; HERPESVIRUS 4, HUMAN; HUMANS; INFECTIOUS MONONUCLEOSIS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOPROLIFERATIVE DISORDERS; MALE;

EID: 77950960418     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.01.002     Document Type: Review

References (56)

1. Young L.S., Rickinson A.B. Epstein-Barr virus: 40 years on. Nat Rev 2004, 4:757-768.
2. Rowe M., Rowe D.T., Gregory C.D., Young L.S., Farrell P.J., Rupani H., et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitta's lymphoma cells. EMBO J 1987, 6:2743-2751.
3. Kennedy G., Komano J., Sugden B. Epstein-Barr virus provides a survival factor to Burkitta's lymphomas. Proc Natl Acad Sci USA 2003, 100:14269-14274.
4. Allday M.J. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitta's lymphoma?. Semin Cancer Biol 2009, 19:366-376.
5. Nagy N., Matskova L., Kis L.L., Hellman U., Klein G., Klein E. The proapoptotic function of SAP provides a clue to the clinical picture of X-linked lymphoproliferative disease. Proc Natl Acad Sci USA 2009, 106:11966-11971.
6. Nagy N., Klein G., Klein E. To the genesis of Burkitt lymphoma: regulation of apoptosis by EBNA-1 and SAP may determine the fate of Ig-myc translocation carrying B lymphocytes. Semin Cancer Biol 2009, 19:407-410.
7. Purtilo D.T. X-linked lymphoproliferative syndrome. An immunodeficiency disorder with acquired agammaglobulinemia, fatal infectious mononucleosis, or malignant lymphoma. Arch Pathol Lab Med 1981, 105:119-121.
8. Coffey A.J., Brooksbank R.A., Brandau O., Oohashi T., Howell G.R., Bye J.M., et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 1998, 20:129-135.
9. Nichols K.E., Harkin D.P., Levitz S., Krainer M., Kolquist K.A., Genovese C., et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci USA 1998, 95:13765-13770.
10. Sayos J., Wu C., Morra M., Wang N., Zhang X., Allen D., et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998, 395:462-469.
11. Veillette A. Immune regulation by SLAM family receptors and SAP-related adaptors. Nat Rev Immunol 2006, 6:56-66.
12. Liu A., Klein G., Bandobashi K., Klein E., Nagy N. SH2D1A expression reflects activation of T and NK cells in cord blood lymphocytes infected with EBV and treated with the immunomodulator PSK. Immunol Lett 2002, 80:181-188.
13. Sayos J., Nguyen K.B., Wu C., Stepp S.E., Howie D., Schatzle J.D., et al. Potential pathways for regulation of NK and T cell responses: differential X-linked lymphoproliferative syndrome gene product SAP interactions with SLAM and 2B4. Int Immunol 2000, 12:1749-1757.
14. Nagy N., Cerboni C., Mattsson K., Maeda A., Gogolak P., Sumegi J., et al. SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines. Int J Cancer 2000, 88:439-447.
15. Nagy N., Maeda A., Bandobashi K., Kis L.L., Nishikawa J., Trivedi P., et al. SH2D1A expression in Burkitt lymphoma cells is restricted to EBV positive group I lines and is downregulated in parallel with immunoblastic transformation. Int J Cancer 2002, 100:433-440.
16. Kis L.L., Nagy N., Klein G., Klein E. Expression of SH2D1A in five classical Hodgkina's disease-derived cell lines. Int J Cancer 2003, 104:658-661.
17. Nagy N., Takahara M., Nishikawa J., Bourdon J.C., Kis L.L., Klein G., et al. Wild-type p53 activates SAP expression in lymphoid cells. Oncogene 2004, 23:8563-8570.
18. + T cells. J Clin Invest 2005, 115:1049-1059.
19. Czar M.J., Kersh E.N., Mijares L.A., Lanier G., Lewis J., Yap G., et al. Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP. Proc Natl Acad Sci USA 2001, 98:7449-7454.
20. Dupre L., Andolfi G., Tangye S.G., Clementi R., Locatelli F., Arico M., et al. SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells. Blood 2005, 105:4383-4389.
21. Morra M., Barrington R.A., Abadia-Molina A.C., Okamoto S., Julien A., Gullo C., et al. Defective B cell responses in the absence of SH2D1A. Proc Natl Acad Sci USA 2005, 102:4819-4823.
22. Al-Alem U., Li C., Forey N., Relouzat F., Fondaneche M.C., Tavtigian S.V., et al. Impaired Ig class switch in mice deficient for the X-linked lymphoproliferative disease gene Sap. Blood 2005, 106:2069-2075.
23. Sylla B.S., Murphy K., Cahir-McFarland E., Lane W.S., Mosialos G., Kieff E. The X-linked lymphoproliferative syndrome gene product SH2D1A associates with p62dok (Dok1) and activates NF-kappa B. Proc Natl Acad Sci USA 2000, 97:7470-7475.
24. Sawyer R.N., Evans A.S., Niederman J.C., McCollum R.W. Prospective studies of a group of Yale University freshmen. I. Occurrence of infectious mononucleosis. J Infect Dis 1971, 123:263-270.
25. Andersson J. Clinical and immunological considerations in Epstein-Barr virus-associated diseases. Scand J Infect Dis Suppl 1996, 100:72-82.
26. Callan M.F., Steven N., Krausa P., Wilson J.D., Moss P.A., Gillespie G.M., et al. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med 1996, 2:906-911.
27. Verbeke C.S., Wenthe U., Bergler W.F., Zentgraf H. Characterization of the expanded T cell population in infectious mononucleosis: apoptosis, expression of apoptosis-related genes, and Epstein-Barr virus (EBV) status. Clin Exp Immunol 2000, 120:294-300.
28. Magrath I. The pathogenesis of Burkitta's lymphoma. Adv Cancer Res 1990, 55:133-270.
29. Rochford R., Cannon M.J., Moormann A.M. Endemic Burkitta's lymphoma: a polymicrobial disease?. Nat Rev Microbiol 2005, 3:182-187.
30. Dalla-Favera R., Bregni M., Erikson J., Patterson D., Gallo R.C., Croce C.M. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982, 79:7824-7827.
31. Chen F., Zou J.Z., di Renzo L., Winberg G., Hu L.F., Klein E., et al. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol 1995, 69:3752-3758.
32. Babcock G.J., Decker L.L., Volk M., Thorley-Lawson D.A. EBV persistence in memory B cells in vivo. Immunity 1998, 9:395-404.
33. Purtilo D.T., Cassel C.K., Yang J.P., Harper R. X-linked recessive progressive combined variable immunodeficiency (Duncana's disease). Lancet 1975, 1:935-940.
34. Seemayer T.A., Gross T.G., Egeler R.M., Pirruccello S.J., Davis J.R., Kelly C.M., et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res 1995, 38:471-478.
35. Egeler R.M., de Kraker J., Slater R., Purtilo D.T. Documentation of Burkitt lymphoma with t(8;14) (q24;q32) in X-linked lymphoproliferative disease. Cancer 1992, 70:683-687.
36. Strahm B., Rittweiler K., Duffner U., Brandau O., Orlowska-Volk M., Karajannis M.A., et al. Recurrent B-cell non-Hodgkin's lymphoma in two brothers with X-linked lymphoproliferative disease without evidence for Epstein-Barr virus infection. Br J Haematol 2000, 108:377-382.
37. Turner A.M., Berdoukas V.A., Tobias V.H., Ziegler J.B., Toogood I.R., Mulley J.C., et al. Report on the X-linked lymphoproliferative disease in an Australian family. J Paediatr Child Health 1992, 28:184-189.
38. Sharifi R., Sinclair J.C., Gilmour K.C., Arkwright P.D., Kinnon C., Thrasher A.J., et al. SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease. Blood 2004, 103:3821-3827.
39. Masucci M.G., Szigeti R., Ernberg I., Masucci G., Klein G., Chessels J., et al. Cellular immune defects to Epstein-Barr virus-determined antigens in young males. Cancer Res 1981, 41:4284-4291.
40. Sumegi J., Huang D., Lanyi A., Davis J.D., Seemayer T.A., Maeda A., et al. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 2000, 96:3118-3125.
41. Sullivan J.L. The abnormal gene in X-linked lymphoproliferative syndrome. Curr Opin Immunol 1999, 11:431-434.
42. Williams H., Macsween K., McAulay K., Higgins C., Harrison N., Swerdlow A., et al. Analysis of immune activation and clinical events in acute infectious mononucleosis. J Infect Dis 2004, 190:63-71.
43. Rohde M., Daugaard M., Jensen M.H., Helin K., Nylandsted J., Jaattela M. Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev 2005, 19:570-582.
44. Song Z., Krishna S., Thanos D., Strominger J.L., Ono S.J. A novel cysteine-rich sequence-specific DNA-binding protein interacts with the conserved X-box motif of the human major histocompatibility complex class II genes via a repeated Cys-His domain and functions as a transcriptional repressor. J Exp Med 1994, 180:1763-1774.
45. Partridge J.J., Lopreiato J.O., Latterich M., Indig F.E. DNA damage modulates nucleolar interaction of the Werner protein with the AAA ATPase p97/VCP. Mol Biol Cell 2003, 14:4221-4229.
46. Braun R.J., Zischka H., Madeo F., Eisenberg T., Wissing S., Buttner S., et al. Crucial mitochondrial impairment upon CDC48 mutation in apoptotic yeast. J Biol Chem 2006, 281:25757-25767.
47. Vandermoere F., El Yazidi-Belkoura I., Slomianny C., Demont Y., Bidaux G., Adriaenssens E., et al. The valosin-containing protein (VCP) is a target of Akt signaling required for cell survival. J Biol Chem 2006, 281:14307-14313.
48. Tsujimoto Y., Tomita Y., Hoshida Y., Kono T., Oka T., Yamamoto S., et al. Elevated expression of valosin-containing protein (p97) is associated with poor prognosis of prostate cancer. Clin Cancer Res 2004, 10:3007-3012.
49. Lauten M., Schrauder A., Kardinal C., Harbott J., Welte K., Schlegelberger B., et al. Unsupervised proteome analysis of human leukaemia cells identifies the Valosin-containing protein as a putative marker for glucocorticoid resistance. Leukemia 2006, 20:820-826.
50. Chen G., Tai A.K., Lin M., Chang F., Terhorst C., Huber B.T. Increased proliferation of CD8+ T cells in SAP-deficient mice is associated with impaired activation-induced cell death. Eur J Immunol 2007, 37:663-674.
51. Snow A.L., Marsh R.A., Krummey S.M., Roehrs P., Young L.R., Zhang K., et al. Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. J Clin Investig 2009, 119:2976-2989.
52. Bellan C., Lazzi S., Hummel M., Palummo N., de Santi M., Amato T., et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood 2005, 106:1031-1036.
53. Muller J.R., Janz S., Goedert J.J., Potter M., Rabkin C.S. Persistence of immunoglobulin heavy chain/c-myc recombination-positive lymphocyte clones in the blood of human immunodeficiency virus-infected homosexual men. Proc Natl Acad Sci USA 1995, 92:6577-6581.
54. Evan G.I., Wyllie A.H., Gilbert C.S., Littlewood T.D., Land H., Brooks M., et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992, 69:119-128.
55. Capoulade C., Bressac-de Paillerets B., Lefrere I., Ronsin M., Feunteun J., Tursz T., et al. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene 1998, 16:1603-1610.
56. Lindstrom M.S., Klangby U., Wiman K.G. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene 2001, 20:2171-2177.